期刊文献+

糖皮质激素对狼疮性肾炎患者活动性作用与肾内B淋巴细胞刺激因子的相关性 被引量:3

Study of correlation between glucocorticoid for lupus nephritis active role and renal B lymphocyte stimulator
下载PDF
导出
摘要 目的探讨糖皮质激素(GC)对狼疮性肾炎(LN)患者活动性作用与肾内B淋巴细胞刺激因子(Bly S)的相关性。方法采用免疫组化法及ELISA法检测LN患者与健康体检者血清内及正常肾组织内的Bly S表达水平。结果 LN患者血清内及肾内Bly S表达水平高于正常对照者(P<0.05),GC治疗>4周组的LN患者肾内Bly S水平及SLE-DAI评分低于未经过GC治疗的LN患者,比较具有统计学意义(P<0.05)。结论 GC减轻LN患者疾病活动性的作用可能与GC降低LN患者肾内Bly S表达水平有密切关系。 Objective To study correlation between glucocorticoid for lupus nephritis active role and renal B lymphocyte stimulatorMethods Using immunohistoehemical and ELISA method to detect LN inpatients and healthy persons serum and expression levels of BlySin the normal kidney tissue. Results LN in serum samples from patients with renal and BLyS expression level is higher than that of normal controls ( P 〈 0. 05 ) , the treatment of GC 〉 4 weeks group of LN patients with renal levels of BLyS and SLE-DAI score lower than not after GC treatment of LN patients, with statistical significance (P 〈 0. 05 ). Conclusions The role of GC in reducing disease activity in LN patients may be closely related to the decrease in BlyS expression in LN patients with GC.
作者 涂学君
出处 《齐齐哈尔医学院学报》 2016年第12期1514-1516,共3页 Journal of Qiqihar Medical University
关键词 糖皮质激素 狼疮性肾炎 肾内B淋巴细胞刺激因子 Glucocorticoid Lupus nephritis B lymphocyte stimulator
  • 相关文献

参考文献11

  • 1Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis [" J ]. Clin J Am Soc Nephrol,2010,5 ( 11 ) :2060-2068.
  • 2章丽和,陈晓微,陈阿琼,熊江彪,朱小春.糖皮质激素联合环磷酰胺和来氟米特治疗狼疮性肾炎的临床研究[J].医学研究杂志,2013,42(4):139-144. 被引量:21
  • 3Bhowmik D, Sinha S, Gupt A, et al. Clinical approach to rapidly progressive renal failure[ J]. J Assoc Physicians India,2011,59 : 38-41.
  • 4Avihingsanon Y, Hirankarn N. Major lupus organ involvement: severe lupus nephritis[J]. Lupus,2010,19(12) :1391-1398.
  • 5Pelekanou V, Notas G, Theodoropoulou K, Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal call carcinomas [ J ]. Anal Cell Pathol (Amst) , 2011,34(1-2) :49-60.
  • 6Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [ J ]. Arthritis Rheum, 1997,40 ( 9 ) : 1725.
  • 7Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis [ J ]. Mod Patho1,2011,24( 1 ) :98-107.
  • 8Ramanujam M, Bethunaickan R, Huang W, et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice [ J]. Arthritis Rheum ,2010,62 (5) : 1457-1468.
  • 9Stohl W, Jacob N, Guo S, et al. Constitutive overexpression of BAFF in autoirnmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity [ J ]. Arthritis Rheum ,2010,62 ( 8 ) :2432-2442.
  • 10Jiskra J, Kubinyi J, Telika Z. Radioiodine 131I therapy of hyperthyroidism on an outpatient basis - safe, effective and economic option[ J]. Vnitr Lek ,2012,58 (2) :94-98.

二级参考文献25

  • 1沈义军,张霞.来氟米特治疗狼疮性肾炎的临床随机对照研究[J].中国医疗前沿,2008,3(16). 被引量:5
  • 2胡伟新,刘春蓓,孙海鸥,刘正钊,谢红浪,章海涛,陈惠萍,曾彩虹,刘志红,黎磊石.1352例狼疮性肾炎的临床与免疫学特征[J].肾脏病与透析肾移植杂志,2006,15(5):401-408. 被引量:48
  • 3徐亮,李志,张军,陆进明.血清B淋巴细胞刺激因子在系统性红斑狼疮中的意义[J].中华风湿病学杂志,2007,11(7):417-419. 被引量:4
  • 4Moore PA, Belvedere O, Orr A, et al. BlyS:member of the tumor necrosis family and B lymphocyte stimulator[ J]. Science, 1999 ;285: 260 - 263.
  • 5Bombardier C, Gladman DD, Urowiz MB, et al. Derivation on the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE [ J]. Arthritis Rheum, 1992;35:630 - 640.
  • 6Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia autoim- mune disease in TALL- 1 transgenetic mice[ J]. Proc Natl Acad Sci USA, 2000 ;97:3370 - 3375.
  • 7Ramanujam M, Davidson A. BAFF blockade for systemic lupus ery- thematosus :will the promise be fufilled? [ J 1. lmmunol Rev, 2008; 223 : 156 - 174.
  • 8Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti - B - lymphocyte stimulator (BlyS) monoclonal antibody:a phase I trail in patients with systemic lupus erythematosus[ J. Arthritis Res Ther, 2008 ; 10 : R109.
  • 9Wallance DJ, Stohl W, Furie RA, et al. A phase II, randomized, double - blind, placebo - controlled, dose - ranging study of beli- mumab in patients with active systemic lupus erythematosus[ J]. Ar- thritis Rheum, 2009 ;61 : 1168 - 1178.
  • 10Furie R, Petri M, Zamani O, et al. A phase III, randomized, place- bo - controlled study of belimumab, a monoclonal antibody that in- hibits B lymphocyte stimulator, in patients with systemic lupus ery- thematosus[J]. Arthritis Rheum, 2011 ;12:3918 -3930.

共引文献27

同被引文献17

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部